Trials / Completed
CompletedNCT06665308
Cognitive Status, Fatigue and Inflammation in Patients With Immune Thrombocytopenia (ITP)
Cognitive Status, Fatigue, and Inflammation in Patients With Immune Thrombocytopenic Purpura (ITP)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 97 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, hospital based, cross-sectional study based on data from patient medical records, including laboratory results. The study will include adult patients with chronic (\> 1 year duration) primary Immune Thrombocytopenia (ITP) only. Patients will be identified based on a laboratory confirmed diagnosis of ITP in the medical records, where there is also a physician-confirmed diagnosis of primary ITP. If patients consent to take part in the study, a routine clinical visit will also serve as the study visit. Patients who do not have a routine visit scheduled during the study period but who would otherwise be eligible may be contacted by the site. In such cases, clinicians may use their discretion to schedule a visit specifically for study purposes. All study participants will have a routine blood test as part of their standard clinical care at the study visit, and this same procedure will be used to collect supplementary blood samples to assess a variety of biomarkers. Data will be collected using a combination of chart review, clinical outcome assessment administration, and laboratory results through blood tests.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No intervention | No intervention will be administered to study participants. Data will be collected using a combination of chart review, clinical outcome assessment administration, and laboratory results through blood tests. |
Timeline
- Start date
- 2025-01-13
- Primary completion
- 2025-11-26
- Completion
- 2025-11-26
- First posted
- 2024-10-30
- Last updated
- 2026-01-26
Locations
4 sites across 2 countries: United States, United Kingdom
Source: ClinicalTrials.gov record NCT06665308. Inclusion in this directory is not an endorsement.